Ernexa Therapeutics Inc. (ERNA) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Ernexa Therapeutics Inc. is a preclinical-stage synthetic allogeneic iMSC therapy company focused on developing cellular therapies for solid tumors (lead candidate ERNA-101) and autoimmune diseases (ERNA-102). The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $47,000 |
| Net Loss | $(8,202,000) | $(6,647,000) |
| Operating Expenses | $2,730,000 | $5,773,000 |
| Cash and Cash Equivalents (End of Period) | $1,918,000 | $5,116,000 |
| Net Cash Used in Operating Activities | $(2,065,000) | $(3,747,000) |
| Accumulated Deficit | $(239,738,000) | $(186,981,000) |
| Current Liabilities | $10,438,000 | $2,938,000 |
Note: Q1 2025 Net Loss includes a $5.3 million non-cash expense related to a forward sales contract.
Material Changes vs. Prior Period
- Revenue: Revenue dropped to zero in Q1 2025 after the company assigned its only revenue-generating customer contract to Factor Bioscience in September 2024.
- Operating Expenses: Total operating expenses decreased by approximately $3.0 million ($5.8M to $2.7M). This reduction was driven primarily by a $1.9 million decrease in occupancy expenses (due to a terminated sublease) and reduced professional fees, partially offset by increased stock-based compensation.
- Other Expenses: "Other expense, net" increased significantly to $5.5 million in Q1 2025 compared to $0.9 million in Q1 2024. This is primarily due to a $5.3 million non-cash expense recognized upon entering a Securities Purchase Agreement (SPA) where the fair value of shares to be issued exceeded the proceeds.
- Liquidity: Cash balances decreased from $1.73 million at year-end 2024 to $1.92 million at March 31, 2025, despite a net cash increase of $189,000 for the quarter funded by debt proceeds.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern. The company does not expect to have sufficient cash or working capital to fund operations for the 12 months following the issuance of this report without raising additional capital.
- Financing Activities:
- Promissory Notes: In March 2025, the company issued two promissory notes totaling $2.3 million to an investor (Charles Cherington), maturing June 15, 2025, or upon a subsequent capital raise of $5 million.
- Securities Purchase Agreement (SPA): On March 31, 2025, the company entered an SPA to sell approx. 58.3 million shares and 11.0 million pre-funded warrants. The First Closing occurred April 2, 2025, raising $1.1 million. The Second Closing ($6.2 million) is contingent on shareholder approval at the June 2, 2025 Annual Meeting.
- Nasdaq Compliance Risks: The company received notices from Nasdaq regarding non-compliance with the Bid Price Rule (minimum $1.00) and Market Value of Listed Securities (MVLS) Rule (minimum $35 million). The company plans to seek shareholder approval for a reverse stock split (1-for-10 to 1-for-15) to regain compliance. Failure to comply could result in delisting.
- Unusual Items: The $5.3 million "Forward sales contract expense" is a non-cash charge resulting from the accounting treatment of the SPA entered on the last day of the quarter.
Investor Verification Checklist
- Capital Raise Execution: Verify the outcome of the shareholder vote on June 2, 2025, regarding the Second Closing of the SPA and the Reverse Stock Split Proposal.
- Debt Maturity: Confirm the repayment status of the $2.3 million promissory notes due June 15, 2025, or the successful execution of the subsequent capital raise required to trigger maturity.
- Nasdaq Status: Monitor Nasdaq communications regarding compliance with the Bid Price and MVLS rules by the June 30 and July 7, 2025 deadlines.
- Cash Burn Rate: Assess the sufficiency of the $1.9 million cash balance against the projected operating burn rate of approximately $2.1 million per quarter.
- Related Party Transactions: Review the terms of the promissory notes issued to Charles Cherington, a significant shareholder and former board member.